Epadol NEO capsules 1 g. №30

Description

Epadol Composition
active substance: 1 capsule contains 1000 mg of ethyl esters of omega-3 acids, which include:

eicosapentaenoic acid 300 mg;
docosahexaenoic acid 200 mg;
other fatty acids 498 mg;
d-α-tocopherol (vitamin E) 2 mg;
excipients: gelatin, glbcerin (in the gelatin capsule shell).

Epadol Dosage form
Soft capsules.

Basic physical and chemical properties: soft gelatin capsules from light yellow to dark yellow, oval in shape, with a seam. The content of the capsule is an oily liquid from light yellow to dark yellow in color with a specific odor.

Pharmacological group
Omega-3 triglycerides, including other esters and acids. ATX code С10А Х06.

Pharmacological properties

Pharmacodynamics.

The omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are essential fatty acids.

The drug actively affects blood plasma lipids, reducing the level of triglycerides, low and very low density lipoproteins (VLDL). The drug affects hemostasis and reduces the risk of thrombus formation by affecting the aggregation ability of platelets; moderately lowers blood pressure.

The normalization of the blood lipid spectrum also occurs due to a decrease in the synthesis of triglycerides in the liver, since EPA and DHA inhibit the esterification of other fatty acids, as well as due to a decrease in the amount of free fatty acids (the amount of peroxisome β-oxidation of fatty acids increases), which are involved in the synthesis of triglycerides … A decrease in triglyceride synthesis leads to a decrease in VLDL levels.

Alpha-tocopherol is an antioxidant that prevents the oxidation of polyunsaturated fatty acids.

Epadol Pharmacokinetics.

Pharmacokinetic data are not available.

Indications
As a primary prevention of atherosclerosis and cardiovascular diseases.

As part of the complex therapy of atherosclerosis, coronary heart disease, arterial hypertension; for secondary prevention of myocardial infarction as an addition to standard treatment methods (for example statins, antiplatelet agents, beta-blockers, ACE inhibitors); with hypertriglyceridemia, in addition to diet therapy, if the latter is not effective enough.

Contraindications
Hypersensitivity to any component of the drug. Exacerbation of chronic cholecystitis, exacerbation of chronic pancreatitis, exacerbation of diseases of the hepatobiliary system, cholelithiasis, pathological conditions, including hemorrhagic syndrome.

Interaction with other medicinal products and other forms of interaction
It is not recommended to prescribe in conjunction with fibrates due to lack of clinical experience. Prescribing the drug Epadol Neo concurrently with warfarin did not lead to hemorrhagic complications, however, in the case of combined use of these drugs or discontinuation of Epadol Neo treatment, prothrombin time should be monitored.